1. 1) Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ. Evaluation of dose-reduced direct oral anticoagulant therapy. Am. J. Med., 129, 1198–1204 (2016).
2. 2) Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 356, j510 (2017).
3. 3) Okumura Y, Yokoyama K, Matsumoto N, et al. Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J. Arrhythm., 33, 289–296 (2017).
4. 4) Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients—Fushimi AF Registry. Circ. J., 81, 1278–1285 (2017).
5. 5) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 365, 981–992 (2011).